Menu Back toSession 4 Track 1 & 2: Evaluation of Digital Technologies to Demonstrate Clinical and Analytical Validation

Digital Technology in Clinical Trials

This event is now offered in a new entirely virtual format.


Session 4 Track 1 & 2: Evaluation of Digital Technologies to Demonstrate Clinical and Analytical Validation

Session Chair(s)

Paul  Upham

Paul Upham

  • Head, Smart Devices
  • Roche / Genentech, United States
A critical aspect in the introduction of digital tools to clinical trials is assuring that you can demonstrate a valid clinical association between the tool’s output and the targeted clinical condition. You’ll learn from experts about how to do that and how to provide analytical validation that your digital tool correctly processes input data to generate accurate, reliable, and precise output data. Finally, learn how to ensure that your output data achieves your intended purpose in your target population in the context of clinical care.
Learning Objective :

At the conclusion of this session, participants should be able to:

  • Describe the basic approach for planning the process of clinical evaluation of a digital tool
  • Understand the difference between: valid clinical association, analytical validation, and clinical validation
  • Understand how these activities fit in the broader context of the clinical evaluation of digital tools and their use in clinical trials

Speaker(s)

Ariel  Dowling, PhD

Speaker

Ariel Dowling, PhD

  • Director of Digital Strategy
  • Takeda Pharmaceuticals, United States
Jessilyn  Dunn, PhD

Speaker

Jessilyn Dunn, PhD

  • Assistant Professor of Biomedical Engineering
  • Duke University, United States
Thomas  Haag

Speaker

Thomas Haag

  • Principal Consultant
  • Cardinal Solutions Consuting, LLC, United States
Thomas  Switzer, MEd

Speaker

Thomas Switzer, MEd

  • gRED Digital Health Scientist
  • Genentech, A Member of the Roche Group, United States